Decreased antibiotic utilization after implementation of a guideline for inpatient cellulitis and cutaneous abscess

Archives of Internal Medicine

Volumn 171, Issue 12, 2011, Pages 1072-1079

  Jenkins, Timothy C ^a,b,c   Knepper, Bryan C ^a   Sabel, Allison L ^a,d   Sarcone, Ellen E ^a,b   Long, Jeremy A ^a,b   Haukoos, Jason S ^a,b,d   Morgan, Steven J ^a,c   Biffl, Walter L ^a,c   Steele, Andrew W ^a,b,c   Price, Connie S ^a,b   Mehler, Philip S ^a,b   Burman, William J ^a,b,c  

^a DENVER HEALTH MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d Global Health and Health Disparities   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; VANCOMYCIN;

ADULT; ANTIBACTERIAL ACTIVITY; ARTICLE; CELLULITIS; CONSULTATION; CULTURE TECHNIQUE; FEMALE; GRAM NEGATIVE BACTERIUM; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL PARAMETERS; MICROBIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SKIN ABSCESS; STANDARDIZATION; TREATMENT FAILURE;

ABSCESS; ADULT; ANTI-BACTERIAL AGENTS; CELLULITIS; FEMALE; HUMANS; INPATIENTS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; SKIN DISEASES;

EID: 79960110982     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2011.29     Document Type: Article

References (42)

1. DeFrances CJ, Lucas CA, Buie VC, Golosinskiy A. 2006 National Hospital Discharge Survey. Natl Health Stat Report. 2008;(5):1-20.
2. Popovic JR. 1999 National Hospital Discharge Survey: annual summary with detailed diagnosis and procedure data. Vital Health Stat 13. 2001;(151):i-v, 1-206.
3. Moran GJ, Krishnadasan A, Gorwitz RJ, et al; EMERGEncy ID Net Study Group. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355(7):666-674.
4. Spellberg B, Talbot GH, Boucher HW, et al; Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials. Clin Infect Dis. 2009;49(3):383-391.
5. Bernard P, Bedane C, Mounier M, Denis F, Catanzano G, Bonnetblanc JM. Streptococcal cause of erysipelas and cellulitis in adults: a microbiologic study using a direct immunofluorescence technique. Arch Dermatol. 1989;125(6):779-782. (Pubitemid 19161120)
6. Eriksson B, Jorup-Rönström C, Karkkonen K, Sjöblom AC, Holm SE. Erysipelas: clinical and bacteriologic spectrum and serological aspects. Clin Infect Dis. 1996; 23(5):1091-1098. (Pubitemid 26367499)
7. Carratalà J, Rosón B, Fernández-Sabé N, et al. Factors associated with complications and mortality in adult patients hospitalized for infectious cellulitis. Eur J Clin Microbiol Infect Dis. 2003;22(3):151-157. (Pubitemid 36461364)
8. Hepburn MJ, Dooley DP, Skidmore PJ, Ellis MW, Starnes WF, Hasewinkle WC. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med. 2004;164(15):1669-1674. (Pubitemid 39037946)
9. Jenkins TC, Sabel AL, Sarcone EE, Price CS, Mehler PS, Burman WJ. Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. Clin Infect Dis. 2010;51(8):895-903.
10. Graham DR, Lucasti C, Malafaia O, et al. Ertapenem once daily versus piperacillintazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis. 2002;34(11):1460-1468. (Pubitemid 34553705)
11. Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010;51(6):641-650.
12. Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother. 2008;52(1):37-44.
13. Graham DR, Talan DA, Nichols RL, et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin Infect Dis. 2002;35(4):381-389. (Pubitemid 34852567)
14. Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis. 2007;44(6):777-784. (Pubitemid 46365300)
15. Stevens DL, Bisno AL, Chambers HF, et al; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections [published correction to dosage error appears in Clin Infect Dis. 2006;15;42(8):1219]. Clin Infect Dis. 2005;41(10):1373-1406.
16. Rajendran PM, Young D, Maurer T, et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother. 2007;51(11):4044-4048. (Pubitemid 350057804)
17. Fridkin SK, Hageman JC, Morrison M, et al; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005;352(14): 1436-1444.
18. Paydar KZ, Hansen SL, Charlebois ED, Harris HW, Young DM. Inappropriate antibiotic use in soft tissue infections. Arch Surg. 2006;141(9):850-856.
19. Chen DK, McGeer A, de Azavedo JC, Low DE; Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med. 1999;341(4):233-239.
20. Johnson L, Sabel A, Burman WJ, et al. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med. 2008;121(10): 876-884.
21. Lautenbach E, Synnestvedt M, Weiner MG, et al. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol. 2010;31(1):47-53.
22. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002;235(3):363-372. (Pubitemid 34183887)
23. Gravel D, Miller M, Simor A, et al; Canadian Nosocomial Infection Surveillance Program. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis. 2009;48(5):568-576.
24. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis. 2006; 12(3):409-415.
25. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med. 2001;29(6):1109-1115. (Pubitemid 32554320)
26. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG; CAPITAL Study Investigators. A controlled trial of a critical pathway for treatment of community-acquired pneumonia: Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA. 2000;283(6):749-755. (Pubitemid 30084614)
27. Dellit TH, Chan JD, Skerrett SJ, Nathens AB. Development of a guideline for the management of ventilator-associated pneumonia based on local microbiologic findings and impact of the guideline on antimicrobial use practices. Infect Control Hosp Epidemiol. 2008;29(6):525-533. (Pubitemid 351918031)
28. Schuetz P, Christ-Crain M, Thomann R, et al; ProHOSP Study Group. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009; 302(10):1059-1066.
29. Hauck LD, Adler LM, Mulla ZD. Clinical pathway care improves outcomes among patients hospitalized for community-acquired pneumonia. Ann Epidemiol. 2004; 14(9):669-675. (Pubitemid 39233628)
30. Gabow P, Eisert S, Wright R. Denver Health: a model for the integration of a public hospital and community health centers. Ann Intern Med. 2003;138(2):143-149. (Pubitemid 36222502)
31. Wong CH, Khin LW, Heng KS, Tan KC, Low CO. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med. 2004;32(7):1535-1541.
32. Blankenship RB, Baker T. Imaging modalities in wounds and superficial skin infections. Emerg Med Clin North Am. 2007;25(1):223-234. (Pubitemid 46497616)
33. Swartz MN. Clinical practice: cellulitis. N Engl J Med. 2004;350(9):904-912.
34. Dall L, Peterson S, Simmons T, Dall A. Rapid resolution of cellulitis in patients managed with combination antibiotic and anti-inflammatory therapy. Cutis. 2005; 75(3):177-180. (Pubitemid 40521814)
35. Polk RE, Fox C, Mahoney A, Letcavage J, MacDougall C. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clin Infect Dis. 2007;44(5):664-670.
36. Schmid MR, Kossmann T, Duewell S. Differentiation of necrotizing fasciitis and cellulitis using MR imaging. AJR Am J Roentgenol. 1998;170(3):615-620. (Pubitemid 28106647)
37. Gerber MA. Antibiotic resistance in group A streptococci. Pediatr Clin North Am. 1995;42(3):539-551.
38. Kaplan EL. Recent evaluation of antimicrobial resistance in beta-hemolytic streptococci. Clin Infect Dis. 1997;24(suppl 1):S89-S92.
39. Huovinen P. Resistance to trimethoprim-sulfamethoxazole. Clin Infect Dis. 2001; 32(11):1608-1614. (Pubitemid 32458729)
40. Clancy MJ, Graepler A, Breese PE, Price CS, Burman WJ. Widespread emergence of methicillin resistance in community-acquired Staphylococcus aureus infections in Denver. South Med J. 2005;98(11):1069-1075. (Pubitemid 41780345)
41. Grimshaw JM, Shirran L, Thomas R, et al. Changing provider behavior: an overview of systematic reviews of interventions. Med Care. 2001;39(8)(suppl 2): II2-II45.
42. Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA; Cochrane Effective Practice and Organization of Care Review Group. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. BMJ. 1998;317(7156): 465-468. (Pubitemid 28368041)